What does BI-RADS (Breast Imaging Reporting and Data System) category 1 indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

BI-RADS Category 1: Negative Mammogram

BI-RADS category 1 indicates a completely negative mammogram with symmetric breasts and no masses, architectural distortion, or suspicious calcifications present 1.

What This Means Clinically

A BI-RADS 1 assessment represents the best possible mammographic outcome. The examination shows:

  • Symmetric breasts bilaterally
  • No masses detected
  • No architectural distortion
  • No suspicious calcifications

This is fundamentally different from BI-RADS 2 (benign findings), where actual findings may be present but are definitively benign (such as calcifying fibroadenomas, oil cysts, lipomas, or vascular calcifications) 1.

Management Recommendation

For BI-RADS category 1, return to routine annual screening mammography 1. No additional imaging, follow-up, or intervention is needed beyond age-appropriate screening intervals.

Important Clinical Caveat

If a palpable mass or clinical concern exists despite BI-RADS 1 imaging, do not dismiss the clinical finding. The negative predictive value of negative imaging is high (>96%), but not absolute 2. In cases where:

  • Clinical suspicion remains high despite negative imaging
  • A palpable abnormality persists

Proceed with core needle biopsy for suspicious clinical findings 2. For low clinical suspicion with BI-RADS 1 imaging, observation with physical examination every 3-6 months ± ultrasound for 1-2 years is appropriate, with biopsy if the lesion increases in size 2.

The key principle is that imaging assessment does not override concerning clinical findings—tissue diagnosis may still be warranted when clinical and imaging findings are discordant 2.

References

Guideline

nccn clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

Guideline

breast cancer screening and diagnosis, version 3.2018, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.